Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

378
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
378
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Interventions for the Timely Diagnosis of Pediatric Patients With Cancer: A Scoping Review.

JCO global oncology·2026
Same author

Survival in low- and middle-income countries pediatric cancer: encouraging context expertise to inform conclusions in resource-constrained settings.

Journal of the National Cancer Institute·2026
Same author

A Model-Informed Early Prediction of Methotrexate-Induced Acute Kidney Injury in Pediatric Patients with Osteosarcoma Using Real-World Data: A Multi-center Pharmacokinetic Study.

Clinical pharmacokinetics·2026
Same author

Immune Response and Safety of Anti-NeuGcGM3 Anti-Idiotype Vaccine Racotumomab in Patients With High-Risk Neuroblastoma: An Open-Label, Single-Arm, Multicenter Phase 2 Study in Argentina.

Pediatric blood & cancer·2026
Same author

How We Approach Intraocular Retinoblastoma in 2026: Agreement and Disagreement in Four Referral Centers in the USA and Europe.

Pediatric blood & cancer·2026
Same author

Ten-year subtype survival and systemic-therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort study.

Lancet regional health. Americas·2026

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

2.1K

Challenges in Launching a Precision Pediatric Oncology Program in Argentina.

María Mercedes Paladino1,2,3, Nicolás Pinto1,4, David Verón2

  • 1Instituto de Investigaciones en Medicina Traslacional (IIMT), CONICET, Pilar, Buenos Aires, Argentina.

Pediatric Blood & Cancer
|April 5, 2026
PubMed
Summary

The COPPA Project provided free, clinically useful genomic sequencing for childhood cancers in Argentina. Multidisciplinary molecular tumor boards (MTBs) enhanced precision medicine adoption despite identified barriers.

Keywords:
ArgentinaLatin Americaimplementationmolecular tumor boardsprecision oncology

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

849
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
05:18

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant

Published on: October 6, 2023

2.1K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

849
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.1K

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Pediatric cancer care increasingly relies on tumor sequencing for diagnosis and treatment.
  • Genomic diagnostics access is limited in Latin America.
  • The COPPA Project aimed to provide free, clinically valuable genomic sequencing for childhood cancers in Argentina.

Purpose of the Study:

  • Assess the feasibility of delivering clinically useful genomic sequencing for pediatric cancers at no cost.
  • Maximize the clinical value of genomic data through multidisciplinary molecular tumor boards (MTBs).
  • Identify barriers and facilitators for implementing precision medicine in a middle-income setting.

Main Methods:

  • Established a sequencing facility and optimized an NGS panel.
  • Trained technical staff and recruited oncologists.
  • Conducted in-house sequencing, reported results, and held virtual MTB meetings.
  • Administered a survey to MTB participants to assess barriers and facilitators.

Main Results:

  • Sequenced 38 pediatric tumors, with 67% yielding clinically useful genomic findings.
  • Identified barriers including low study demand and oncologists' limited time for MTBs.
  • MTB participation increased participants' knowledge of precision medicine and motivation for genomic testing.

Conclusions:

  • Key barriers and facilitators for implementing precision medicine in pediatric cancer were identified in a middle-income country.
  • Findings can inform future precision medicine initiatives in the region.
  • The COPPA Project demonstrated the potential for accessible genomic sequencing and MTB integration in Latin America.